146例乳腺非特殊型浸润性导管癌分子分型及临床病理特点分析

Molecular subtypes and clinicopathologic characterization in 146 cases with invasive ductal carcinoma of breast-not otherwise specified

目的:探讨《St.Gallen共识》对乳腺非特殊型浸润性导管癌行分子分型与临床病理特点的关系。方法:依照《St.Gallen共识》,采用免疫组织化学染色及HER2 CISH方法对146例乳腺非特殊型浸润性导管癌ER、PR、HER2及Ki-67表达进行检测,行乳腺癌分子分型并对其与临床病理特点进行分析。结果:146例乳腺非特殊型浸润性导管癌中腔面A型(Luminal A型)42.5%(62/146),Luminal B(HER2阴性)型12.3%(18/146),Luminal B(HER2阳性)型15.1%(22/146),HER2过表达型17.1%(25/146),三阴型13.0%(19/146)。肿块大小、淋巴结转移及病理学分级在各亚型中差异有统计学意义(P<0.05)。结论:通过免疫组化检测ER、PR、HER2及Ki-67表达可将乳腺非特殊型浸润性导管癌分成不同的分子分型,对临床评估预后及指导治疗具有一定的意义。

Objective： To explore the relationship between the molecular subtypes and clinicopathologic characterization in patients with invasive ductal carcinoma of breast - not otherwise specified according to （（ St. Gallen）〉 . Methods： 146 cases of invasive ductal carci- noma of breast - not otherwise specified were studied using immunohistochemical staining or HER2 CISH detection with antibody of ER, PR, HER2 and Ki -67 and subclassified according to （（St. Gallen）） . The relationship between molecular subtypes and clinicopathologic characterization were analyzed. Results： The proportions of four molecular subtypes in 146 cases were： Luminal A types 42. 5% （62/146）, Luminal B types （HER2 - ） 12. 3% （18/146） , Luminal B types （HER2 ＋ ） 15. 1% （22/146）, HER2 positive 17. 1% （25/146）, Triple- negative types 13.0% （19/146） . Tumor size, lymph node metastasis and histological grades were significantly different among these types. Conclusion ： According to the expression of ER, PR, HER2 and Ki - 67, invasive ductal carcinoma of breast - not otherwise specified could be classified into subgroups, having a role in evaluating the prognosis and guiding the clinical treatment.